Warning: count(): Parameter must be an array or an object that implements Countable in /home/customer/www/drugtrialsformoney.com/public_html/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 373
Phase I Study of IGM-8444 as a Single Agent and in Combination in Subjects With Relapsed and/or Refractory Solid Cancers - Drug Trials For Money - Paid Clinical Trials

Phase I Study of IGM-8444 as a Single Agent and in Combination in Subjects With Relapsed and/or Refractory Solid Cancers

Phase I Study of IGM-8444 as a Single Agent and in Combination in Subjects With Relapsed and/or Refractory Solid Cancers
Conditions:   Solid Tumor;   Colorectal Cancer;   Gastric Cancer;   Non Hodgkin Lymphoma;   Non-Small Cell Lung Cancer;   Sarcoma;   Chondrosarcoma;   Small Lymphocytic Lymphoma;   Chronic Lymphocytic Leukemia
Interventions:   Drug: IGM-8444;   Drug: FOLFIRI;   Drug: Bevacizumab (and approved biosimilars);   Drug: Birinapant;   Drug: Venetoclax
Sponsor:   IGM Biosciences, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 21, 2021 / by / in
Comments